Popular Trials
Glucagon-like peptide-1 (GLP-1) receptor agonist
Liraglutide for Autonomic Nervous System Disorders
Recruiting1 awardPhase 2
Norfolk, Virginia
The purpose of this study is to conduct an interventional, one year, randomized, double blind, placebo-controlled trial with Liraglutide in patients with type 2 diabetes (diabetes duration of \>6 months and \<10 years, HbA1c \<10%) to evaluate its effects on the peripheral autonomic nervous system, as well as inflammatory markers, and measures of oxidative and nitrosative stress.
GLP-1 Agonist
Liraglutide for Coronary Heart Disease
Recruiting2 awardsPhase 4
Miami, Florida
This trial tests if liraglutide, a diabetes medication, can reduce heart fat inflammation in patients with type 2 diabetes and coronary artery disease. By lowering inflammation, it may help reduce artery plaque buildup. The study involves 40 patients who will receive liraglutide. Liraglutide is approved for the treatment of type 2 diabetes and obesity, with evidence showing it can reduce cardiovascular events.
Glucagon-like peptide-1 receptor agonist
Liraglutide for Type 2 Diabetes
Recruiting3 awardsPhase 4
Philadelphia, Pennsylvania
This trial tests if Liraglutide can reduce stress in fat tissue and improve health in obese patients with type 2 diabetes. The medication helps control blood sugar and appetite, potentially offering better management for these patients. Liraglutide is used for weight management and glycemic control in patients with type 2 diabetes.
Glucagon-like peptide-1 receptor agonist
LAPS-Exendin for Diabetes
Recruiting0 awardsPhase 1
California, California
This trial is testing a new drug, HM11260C, in people with Type 2 Diabetes Mellitus. The study aims to see if this drug can help control blood sugar levels by slowing down how fast food leaves the stomach and improving insulin production. Researchers will also check how safe and acceptable the treatment is. An existing diabetes medication, liraglutide (Victoza), will be used for comparison.
Popular Filters
Trials With No Placebo
Glucagon-like peptide agonist
Liraglutide for Type 1 Diabetes
Recruiting2 awardsPhase 3
Buffalo, New York
This trial will test the effect of liraglutide, a long-acting glucagon-like peptide-1 analog, on blood sugar control in adolescents with Type 1 diabetes. Liraglutide is already approved for the treatment of Type 2 diabetes in adults.
Incretin Mimetic
Holding vs. Continuing Incretin-Based Therapies for Type 2 Diabetes
Recruiting1 award1 criteria
Weston, Florida
This trial aims to see if stopping incretin-based therapy before endoscopy can reduce the chances of having too much food in the stomach. The main things they are looking at are: - The
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.